Form 8-K DEPOMED INC For: Nov 07

Go back to Form 8-K DEPOMED INC For: Nov 07

Leerink Keeps Depomed (DEPO) at 'Outperform'; Disappointing Q3 Steps-up Pressure to Sell

November 8, 2016 11:00 AM EST

Leerink affirms its Outperform rating and $22 price target on Depomed (Nasdaq: DEPO) following Q3 results and update on Monday night.

Analyst Jason M. Gerberry commented today, DEPO reported disappointing 3Q results, missing our/Streets revenue forecasts by 13% and reducing 2016 revenue guidance for the third consecutive qtr. The miss... More